Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.33 |
| ▸ | FYN | P06241 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6757593 | 0.93 | LTB4R (0.47) | LTB4RHSD17B10MCHR1FYN | |
| SCHEMBL6765800 | 0.83 | LTB4R (0.44) | LTB4RHPGDALDH1A1RAB9ANPC1 | |
| SCHEMBL6760792 | 0.81 | LTB4R (0.52) | LTB4RMCHR1RAB9ANPC1 | |
| SCHEMBL6923894 | 0.81 | LTB4R (0.46) | LTB4R | |
| SCHEMBL6759707 | 0.80 | LTB4R (0.49) | LTB4RMCHR1SMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL6760886 | 0.77 | LTB4R (0.42) | LTB4R | |
| SCHEMBL6759621 | 0.75 | LTB4R (0.53) | LTB4RHSD17B10HPGDALDH1A1MEN1 | |
| SCHEMBL6760505 | 0.75 | LTB4R (0.45) | LTB4R | |
| SCHEMBL6765798 | 0.75 | LTB4R (0.57) | LTB4R | |
| SCHEMBL6977207 | 0.74 | LTB4R (0.55) | LTB4RSMN1; SMN2ALDH1A1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040247523-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-12-09 | — | — | US | disclosed |
| US-6770259-B2 | ADMINISTEING RADIOLABELED LEUKOTRIENE (LTB4) BINDING AGENT AND A RADIOLABELED PERFUSION IMAGING AGENT; CONCURRENTLY DETECTING THE RADIOLABELED LTB4 BINDING AGENT BOUND AT THE LTB4 RECEPTOR AND THE RADIOLABELED PERFUSION IMAGING AGENT | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-03 | — | — | US | disclosed |
| EP-1347784-A2 | SIMULTANEOUS DUAL ISOTOPE IMAGING OF CARDIAC PERFUSION AND CARDIAC INFLAMMATION | Bristol-Myers Squibb Pharma Company (US) | 2003-10-01 | — | — | EP | disclosed |
| US-20030124053-A1 | Radiopharmaceuticals for imaging infection and inflammation | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-03 | — | — | US | disclosed |
| EP-0999856-B1 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-05-14 | — | — | EP | disclosed |
| EP-1293214-A2 | LTB4 antagonists and radiopharmaceuticals for imaging infection and inflammation | Bristol-Myers Squibb Pharma Company (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20030007927-A1 | Radiopharmaceuticals for imaging infection and inflammation | BARRETT JOHN A (US) | 2003-01-09 | — | — | US | disclosed |
| US-20030003049-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | LANTHEUS MEDICAL IMAGING, INC. | 2003-01-02 | — | — | US | disclosed |
| US-6416733-B1 | RADIOPHARMACEUTICALS BIND IN VIVO TO THE LEUKOTRIENE B4 (LTB4) RECEPTOR ON THE SURFACE OF LEUKOCYTES WHICH ACCUMULATE AT THE SITE OF INFECTION AND INFLAMMATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-09 | — | — | US | disclosed |
| WO-2002036173-A2 | SIMULTANEOUS DUAL ISOTOPE IMAGING OF CARDIAC PERFUSION AND CARDIAC INFLAMMATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030124053-A1 | Radiopharmaceuticals for imaging infection and inflammation | LTB4R, LTB4R2, LTA4H | LTB4R 1/4885HSD17B10 1324/4885MCHR1 561/4885 |
| US-20030007927-A1 | Radiopharmaceuticals for imaging infection and inflammation | LTB4R, LTB4R2, LTA4H | LTB4R 1/4885HSD17B10 1324/4885MCHR1 561/4885 |
| US-20040247523-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | LTB4R, LTB4R2, FABP3 | LTB4R 1/4885HSD17B10 1637/4885MCHR1 1593/4885 |
| US-20030003049-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | LTB4R, LTB4R2, FABP3 | LTB4R 1/4885HSD17B10 1637/4885MCHR1 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.